This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Madhavan, T. Articles by Quinn, E. L. Search for Related Content PubMed PubMed Citation Articles by Madhavan, T. Articles by Quinn, E. L.

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1976 September; 10(3): 464-466
Copyright © 1976 American Society for Microbiology. All Rights Reserved.

Effect of Renal Failure and Dialysis on the Serum Concentration of the Aminoglycoside Amikacin

^* Division of Infectious Disease, Henry Ford Hospital, Detroit, Michigan 48202
Division of Nephrology, University of Michigan, Ann Arbor, Michigan 48104

ABSTRACT

Serum and dialysate levels of amikacin were determined at appropriate intervals after a 300-mg intravenous dose as a continuous infusion in six patients with end-stage renal failure undergoing hemodialysis and in three patients on peritoneal dialysis. The mean serum half-life of amikacin was 3.75 h during (or after) hemodialysis and 29 h during (or after) peritoneal dialysis. Although not on hemodialysis in the same six patients, the serum half-life was 28 h. The results indicate that the maintenance dose of amikacin should be markedly decreased in patients with severe renal failure even if they are treated with peritoneal dialysis, and that serial serum antibiotic concentrations are essential to prevent cumulative toxicity of the drug.